|
|
3줄모양
|
|
 |
FEUnnMswToRDZUhxp |
 |
419 |
|
 |
| Thanks funny site <a href=" http://teazr.me/01/renwick-gallery/#charges ">adcirca limited distribution</a> Pharmacyclics is developing the drug with J&J's Janssen Biotech unit. Both asked the Food and Drug Administration for priority review of ibrutinib to treat mantle cell lymphoma and chronic lymphocytic leukemia. The goal is to shorten the FDA's review period to six months from 10. Ibrutinib is now in phase two trials. Most treatments don't receive approval until after phase three. |
|
 |
Randal |
 |
2018-10-30 23:52:01 |
|
|
|
|
|
|
|
|
|
